This pattern is consistent with pre-arranged 10b5-1 plans or routine equity compensation management. No immediate concern for fundamentals, but monitor for additional selling or changes in guidance.
ZLAB drugs
ZLAB drug pipeline →Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Zai Lab CEO Du Ying exercised stock options to acquire shares and sold a portion of her holdings in the open market, generating approximately $2.15 million in proceeds from sales. The majority of transactions were non-cash option exercises and tax withholding events related to equity compensation. Total open-market sales represent less than 0.1% of the company's $2.1B market cap.
Key Financial Metrics
Key Facts
- CEO Du Ying conducted a series of derivative exercises and open-market sales over a 6-day period.
- Total open-market sales: 101,067 shares sold for $1,942,725.38 across three transactions.
- Option exercises totaled 663,839 shares, with cash payments of $628,300.08; most were at $0 exercise price.
- Tax withholding transaction: 116,936 shares surrendered valued at $2.27 million (non-cash disposition).
- All trading activity was conducted by the CEO; no other insiders involved.
Financial Impact
$1.94M in open-market sales and $628K in option exercise payments; $2.27M in shares withheld for taxes.
Risk Factors
- Perception of insider减持 despite likely pre-planned nature
- Potential dilution from newly exercised shares
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (11 trades, 7d window) | cluster-ZLAB-1773346367134 |
Track record
23 reports on ZLAB
3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +13.13% at T+20 after the May 7, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $22.60 to $25.48 Now $23.47 +3.85% ▲ +12.74% +12.43% vs SPY
- Oct 23, 202624d ago 8-K Bullish 6/10 Entry $24.03 to $24.34 Now $23.47 −2.33% ▲ +1.29% +0.58% vs SPY
- Aug 21, 202612w ago Insider Cluster Neutral 2/10 Entry $25.64 to $26.17 Now $23.47 −8.46% ▲ +2.07% +1.75% vs SPY
- Aug 13, 202613w ago Insider Cluster Neutral 2/10 Entry $25.90 to $25.64 Now $23.47 −9.38% ▼ −1.00% −0.53% vs SPY
- Aug 13, 202613w ago Insider Cluster Neutral 2/10 Entry $25.90 to $25.64 Now $23.47 −9.38% ▼ −1.00% −0.53% vs SPY
- Aug 12, 202613w ago 144 Neutral 2/10 Entry $25.49 to $26.03 Now $23.47 −7.92% ▲ +2.12% +1.42% vs SPY
- Jul 1, 202619w ago Insider Cluster Neutral 2/10 Entry $19.12 to $19.08 Now $23.47 +22.75% ▼ −0.21% −1.08% vs SPY
- Jun 29, 202620w ago Insider Cluster Neutral 3/10 Entry $19.00 to $19.15 Now $23.47 +23.53% ▲ +0.79% +0.92% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 5/10 Entry $17.64 to $17.07 Now $23.47 −33.05% ▲ +3.23% +3.77% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers